Dr Reddy's and four other drug makers to sell Covid-19 drug Baricitinib in India
Dr Reddy's Laboratories has entered into a royalty-free, non-exclusive voluntary licencing agreement with US-based pharma major Eli Lilly and Company for the manufacture and sale of the drug, Baricitinib. Baricitinib has received 'restricted emergency use approval' from the health ministry's central drugs standard control organisation for use in combination with Remdesivir for treatment of suspected or confirmed COVID-19 patients who require supplemental oxygen, invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO).
image for illustrative purpose
Dr Reddy's Laboratories has entered into a royalty-free, non-exclusive voluntary licencing agreement with US-based pharma major Eli Lilly and Company for the manufacture and sale of the drug, Baricitinib. Baricitinib has received 'restricted emergency use approval' from the health ministry's central drugs standard control organisation for use in combination with Remdesivir for treatment of suspected or confirmed COVID-19 patients who require supplemental oxygen, invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO).
Deepak Sapra, Chief Executive Officer, API and Services, Dr Reddy's Laboratories, said: "From the start, we have been determined to explore every possible avenue against COVID-19. Our collaboration with Lilly will help us make yet another treatment option available to patients in India." Lilly has also issued licences to Cipla, Lupin, Natco and Sun Pharmaceutical to manufacture and sell the low-cost versions of its new COVID-19 drug Baricitinib in India.
